Advertisement
Research Article

Treatment of Terminal Peritoneal Carcinomatosis by a Transducible p53-Activating Peptide

  • Eric L Snyder,

    Affiliations: Howard Hughes Medical Institute, Chevy Chase, Maryland, United States of America, Washington University School of Medicine, St. Louis, Missouri, United States of America

    X
  • Bryan R Meade,

    Affiliation: Department of Cellular and Molecular Medicine, School of Medicine, University of California, San Diego, La Jolla, California, United States of America

    X
  • Cheryl C Saenz,

    Affiliations: Howard Hughes Medical Institute, Chevy Chase, Maryland, United States of America, Department of Reproductive Medicine, School of Medicine, University of California, San Diego, La Jolla, California, United States of America

    X
  • Steven F Dowdy mail

    To whom correspondence should be addressed. E-mail: sdowdy@ucsd.edu

    Affiliations: Howard Hughes Medical Institute, Chevy Chase, Maryland, United States of America, Department of Cellular and Molecular Medicine, School of Medicine, University of California, San Diego, La Jolla, California, United States of America

    X
  • Published: February 17, 2004
  • DOI: 10.1371/journal.pbio.0020036

Media Coverage of this Article

Found additional news media or blog coverage for the article? Please let us know.

Linked Articles

Activating p53 in Cancer Cells with Protein Therapy Shows Preclinical Promise

Synopsis | published 17 Feb 2004 | PLOS Biology
doi:10.1371/journal.pbio.0020058